Viatris Australia
Pharmaceuticals
Established in 1982. Makers of generic medicines. Alphapharm is the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme. Operates a manufacturing plant in Queensland. Acquired by Mylan in 2007 who merged with Upjohn in 2020 to form Viatris. Bought Aspen's portfolio of prescription and over-the-counter products in Australia for $188 million in 2019.

Overall

Owned USA
Rating C
About the Ratings

Company Ownership

Alphapharm Pty Ltd
AUS
Mylan NV
owns 100% of Alphapharm Pty Ltd
NLD
Pharmaceuticals
One the world's largest manufacturers of prescription generic drugs. Merged with Upjohn in 2020 to create Viatris Inc.
Viatris Inc
owns 100% of Mylan NV
USA
Pharmaceuticals
Created in 2020 when Mylan merged with Pfizer's off-patent drug business, Upjohn.

Company Assessment

Alphapharm Pty Ltd
Praise
This company received a packaging performance level of 3 (Advanced) in its 2024 APCO Annual Report. Australian Packaging Covenant Organisation (APCO) is a not-for-profit organisation leading the development of a circular economy for packaging in Australia. Each year, APCO Members are required to submit an APCO Annual Report and Action Plan, which includes an overall performance level from 1 (Getting Started) to 5 (Beyond Best Practice).
Source: APCO (2024)
Information
According to data released by the Australian Tax Office in Jan 2022, this company was one of many local and foreign-based companies that paid no tax in Australia in 2019-20. Please note however that companies pay income tax on profits, not revenue (total income). While some companies use tax havens and loopholes to avoid paying their fair share of tax in Australia, other companies that paid no tax have perfectly legitimate reasons.
Source: ATO (2022)
Mylan NV
Criticism
In August 2017, Mylan agreed to a $465 million settlement in a whistleblower lawsuit. The U.S. Justice Department and several states claimed the company overcharged Medicaid for EpiPens. As part of the settlement, Mylan did not have to admit any wrongdoing. The settlement came as Mylan faced growing complaints about skyrocketing price hikes for EpiPens. Between 2007 and 2016, Mylan increased the price of a two-pack of EpiPens from less than $100 to more than $600.
Changing Markets' 2018 report, 'Hyderabad's Pharmaceutical Pollution Crisis' explores the impacts of pollution from pharmaceutical production sites in the Indian city of Hyderabad, one of the world's largest "bulk drug" manufacturing hubs. Water samples taken by investigators from factories owned by this company found the presence of solvents and/or heavy metals at extremely high concentrations, orders of magnitude higher than maximum regulatory limits or safe exposure levels, which points to substantial human and ecological risk potential.
As You Sow's 2021 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Heather Bresch came in at number 21 on the list, having been paid US$18,509,260 in 2020. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
Information
Mylan, the makers of the EpiPen, an injectable device that is filled with medicine and can stop a life-threatening allergic reaction with immediate effect, have increased the price of the device from $100 in 2008 to above $500 in 2016, making it a hike of over 400 per cent. Epipens only cost a few dollars to make and the price-hike has caused a public outcry.
Viatris Inc
Praise
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change score of B.
Source: CDP (2023)
The 2021 Antimicrobial Resistance (AMR) Benchmark ranks 17 large pharmaceutical companies on their efforts keep medicines and vaccines available, despite the rise of drug resistance. This company was identified as a leader amongst generic medicine manufacturers, receiving a score of 67%.
In 2023, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security score of B-.
Source: CDP (2023)
America's Most Responsible Companies 2022 by Newsweek and Statista recognises the Top 500 most responsible companies in the United States. Companies were evaluated in three areas: environmental (waste, energy use, etc.), social (leadership diversity, employees and philanthropy) and governance (transparency and economic performance). This company received a total score of 76.7/100, ranking 19th in the Health Care & Life Sciences sector, and 167th overall.
World's Most Sustainable Companies of 2024 by TIME and Statista recognises the Top 500 most sustainable companies in the world. From a selection of 5,000 of the world's largest companies, non-sustainable businesses were excluded, and the remaining companies were rated on Commitment & Ratings, Reporting & Transparency, and Environmental & Social Stewardship. This company received a total score of 61.5/100, ranking 263rd overall.
Source: TIME (2024)
Criticism
This company received an S&P Global ESG Score of 30/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 18 Nov 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
In 2022 the median pay for a worker at this company was US$36,865. The CEO was paid 398 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Information
As You Sow's 2023 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Michael Goettler came in at number 53 on the list, having been paid US$14,669,592 in 2022. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
This company has corporate social responsibility claims on its website.
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2024 rankings the public identified 20 issues, which are organised under the headings Workers, Communities, Customers, Shareholders and Environment. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 462nd of 937 companies, and 29th of 41 Pharmaceuticals & Biotech companies.

Company Details

Type:
Wholly-owned subsidiary
Founded:
1982
Employees:
640 (2017)

Contact Details

Address:
Level 1, 30 The Bond, Millers Point, NSW, 2000, Australia
Phone:
02 9298 3999
Freecall:
1800 274 276
Website:
www.viatris.com/en-AU

Products / Brands

Viatris Australia
Dermeze Skin Care
Dermeze Body Wash
Dymadon Pain Relief Tablets
Gastro-Stop Digestive Care
Irish Moss Cold & Flu
Stingose Antiseptic
Tums Digestive Care
Waxsol Eye & Ear Care